CASE STUDY: CRISPR / HEALTHCARE TECHNOLOGY
Mammoth Biosciences
Democratizing disease detection with the world’s first ‘OS for CRISPR.’
The Story
How Mammoth Biosciences came to own 'Crispr Diagnostics'
Mammoth Biosciences is the company behind a CRISPR-based disease detection platform grown out of research conducted at UC Berkeley.
The company’s goal was to become the dominant player in a rapidly growing market, knowing full well that a major competitor was soon to enter.
Our primary objective then was to own the position of ‘Crispr Diagnostics,’ which had the potential to become as big or bigger than the ‘Crispr Therapeutics’ space, which was already developed and has created multibillion-dollar companies.
Strategy and Tactics
We launched Mammoth as the first CRISPR-based platform for disease detection.
We found that the public’s familiarity with CRISPR technology was rooted in the moral pros and cons of gene editing humans. We had to overcome this general skepticism while educating our audience on CRISPR’s enormous untapped potential in disease detection.
The core message focused on the company’s larger vision: democratizing disease detection with the world’s first ‘OS for CRISPR.’
We framed lab experiments and diagnostic products as ‘apps’ which could be easily scaled on the Mammoth platform. This highlighted the specific ways Mammoth was paving the road for CRISPR to come out of the lab and into real life.
The Results
The earned media campaign reached an estimated 217 million viewers - up to 8x that of Mammoth’s top competitors. This wave of publicity triggered a spike in inbounds from investors, partners, and new hires. Just months after Mammoth’s launch, the company raised $23 million, led by top Silicon Valley investor, Mayfield along with 8VC and Apple CEO, Tim Cook, to name a few.
Mammoth Biosciences’ CEO and co-founder Trevor Martin was recognized on both the Forbes’ 2019 30 under 30 and Inc. 30 under 30.
8x
Competitor's Coverage
$23M
Fundraise
919
Social Posts in 2 weeks
1
Forbes 30 Under 30
Wall Street Journal
Beyond health care, Mammoth's long game is to develop a platform that will allow the creation of Crispr-based tests across agriculture, natural resources and forensics.
-Heather Mack
Wired
Called Mammoth Biosciences, the startup is developing point-of-care diagnostic tests that work by using Crispr to pick up bits of genetic material circulating in your blood, spit, or urine—say, a few copies of Zika virus left behind by a mosquito, or some mutations in a cancer cell shed from a tumor.
-Megan Molteni
Engadget
Biotech company Mammoth Biosciences is working on a simple, portable test that would give everyone, from healthcare professionals to just people at home, the ability to detect various diseases, infections and cancers quickly and easily.